clinical pathways doctor

Oncology Clinical Pathways Spotlight

IP Blog | Dave Melin | November 4, 2014

This week in health care trends, our spotlight on oncology clinical pathways and utilization management includes updates about a new pathways collaboration, breast cancer therapy adherence, and the future of clinical pathways.

Read Full Post »

BioBlog Weekly oncology

First Biosimilar, Filgrastim, Filed by FDA Under New Follow on Biologic Pathway (FOB)

IP Blog | Dave Melin | August 24, 2014

This week in healthcare, Sandoz became the first manufacturer to register a biosimilar under the new FOB pathway and a new report shows states struggling to meet even half the American Cancer Society’s benchmarks for cancer treatment and prevention. Filgrastim Marks First Official U.S. Biosimilar Filed Under Pathway [login required] Late last month, Sandoz became […]

Read Full Post »